X

Drug Profile

MLN 3897

Alternative Names: AVE-9897; MLN-3897

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Millennium Pharmaceuticals; sanofi-aventis
Developer Millennium; sanofi-aventis
Class Anti-inflammatories; Small molecules
Mechanism of Action CCR1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Inflammation; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

11 Jul 2008 No development reported - Phase-I for Multiple sclerosis in USA (PO)
14 May 2008 Takeda acquires Millennium
08 Mar 2007 Phase-I clinical trials in Multiple sclerosis in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com